cefadroxil ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 526 50370-12-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefadroxil
  • cefadrox
  • cephadroxil
  • cefadroxil hemihydrate
Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.
  • Molecular weight: 363.39
  • Formula: C16H17N3O5S
  • CLOGP: -2.51
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 132.96
  • ALOGS: -2.96
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 14.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 93 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 78.62 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.39 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 17, 1978 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cross sensitivity reaction 406.20 23.76 69 1778 1900 50601377
Type IV hypersensitivity reaction 253.80 23.76 48 1799 2434 50600843
Rash maculo-papular 121.39 23.76 43 1804 26598 50576679
Oedema 62.01 23.76 36 1811 70145 50533132
Drug hypersensitivity 58.85 23.76 58 1789 250952 50352325
Veillonella infection 27.87 23.76 4 1843 34 50603243
Cellulitis 27.80 23.76 22 1825 70776 50532501
Neisseria infection 27.38 23.76 4 1843 39 50603238
Drug reaction with eosinophilia and systemic symptoms 26.16 23.76 15 1832 28409 50574868
Stomatococcal infection 24.38 23.76 4 1843 87 50603190

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cross sensitivity reaction 183.14 27.61 30 563 1232 29572702

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cross sensitivity reaction 572.96 23.57 99 2092 3268 64493273
Type IV hypersensitivity reaction 266.11 23.57 52 2139 3370 64493171
Rash maculo-papular 103.91 23.57 44 2147 46982 64449559
Oedema 65.44 23.57 40 2151 91895 64404646
Drug hypersensitivity 45.98 23.57 48 2143 237767 64258774
Drug reaction with eosinophilia and systemic symptoms 44.81 23.57 26 2165 54191 64442350
Toxic epidermal necrolysis 36.60 23.57 20 2171 37146 64459395
Anaphylactic reaction 32.07 23.57 23 2168 68641 64427900
Veillonella infection 27.40 23.57 4 2187 42 64496499
Neisseria infection 25.83 23.57 4 2187 64 64496477
Erythema 24.62 23.57 31 2160 187039 64309502

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DB05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
CHEBI has role CHEBI:36047 antibacterial drugs
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Streptococcal tonsillitis indication 41582007
Klebsiella cystitis indication 60867007
Urinary tract infectious disease indication 68566005
Tonsillitis indication 90176007 DOID:10456
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Infection due to Staphylococcus aureus indication 406602003
Prevention of Bacterial Endocarditis off-label use
Impaired renal function disorder contraindication 197663003
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Skin and soft tissue infections caused by susceptible strains of Staphylococcus aureus Indication
Cats Genitourinary tract infections caused by Escherichia coli Indication
Cats Genitourinary tract infections caused by Proteus species Indication
Cats Genitourinary tract infections caused by Staphylococcus aureus Indication
Cats Skin and soft tissue infections caused by Pasteurella multocida Indication
Cats Skin and soft tissue infections caused by Staphylococcus epidermidis Indication
Cats Skin and soft tissue infections caused by Streptococcus species Indication
Dogs Skin and soft tissue infections caused by Staphylococcus aureus Indication
Dogs Genitourinary tract infections caused by Escherichia coli Indication
Dogs Genitourinary tract infections caused by Proteus species Indication
Dogs Genitourinary tract infections caused by Staphylococcus aureus Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Cefa-Tabs HQ Specialty Pharma Corp. 1
Cefa-Drops HQ Specialty Pharma Corp. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.77 acidic
pKa2 9.72 acidic
pKa3 13.53 acidic
pKa4 7.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 15 member 1 Transporter Ki 2.14 WOMBAT-PK
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4018151 VUID
N0000146488 NUI
D00257 KEGG_DRUG
119922-85-9 SECONDARY_CAS_RN
1297878 RXNORM
4018151 VANDF
C0007538 UMLSCUI
CHEBI:53667 CHEBI
CHEMBL1644 ChEMBL_ID
DB01140 DRUGBANK_ID
D002434 MESH_DESCRIPTOR_UI
47965 PUBCHEM_CID
4831 IUPHAR_LIGAND_ID
280111G160 UNII
d00080 MMSL
004959 NDDF
13414000 SNOMEDCT_US
372651006 SNOMEDCT_US
66592-87-8 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3196 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3196 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-4059 TABLET 1000 mg ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9766 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9767 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9947 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9948 TABLET, FILM COATED 1 g ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 10544-135 CAPSULE 500 mg ORAL ANDA 19 sections
CEFADROXIL Human Prescription Drug Label 1 16590-043 CAPSULE 500 mg ORAL ANDA 23 sections
Cefadroxil Human Prescription Drug Label 1 16714-388 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-389 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-390 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 21695-427 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 33261-018 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 42254-146 CAPSULE 500 mg ORAL ANDA 19 sections
CEFADROXIL Human Prescription Drug Label 1 42549-504 CAPSULE 500 mg ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-553 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-553 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-595 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 45865-503 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 50090-0580 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil Human Prescription Drug Label 1 50090-1915 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 52959-428 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 53002-2290 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 54868-3742 CAPSULE 500 mg ORAL ANDA 13 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 54868-5693 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 14 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 54868-5694 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 14 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 55289-589 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 55289-589 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil Human Prescription Drug Label 1 57237-096 CAPSULE 500 mg ORAL ANDA 21 sections